UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the month of October 2025
Commission
File Number: 001-41115
GENENTA
SCIENCE S.P.A.
(Translation
of Registrant’s Name into English)
Via
Olgettina No. 58
20132
Milan, Italy
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This
report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).
Genenta
Science S.p.A. Reports Financial Results for the Six Months Ended June 30, 2025
Genenta
Science S.p.A. (“Genenta”) is furnishing this report on Form 6-K to provide its unaudited consolidated financial statements
as of June 30, 2025, and for the six months ended June 30, 2025, and to provide its Management’s Discussion and Analysis of Financial
Condition and Results of Operations with respect to such financial statements.
The
unaudited consolidated financial statements as of June 30, 2025, and for the six months ended June 30, 2025, are attached to this Form
6-K as Exhibit 99.1. Management’s Discussion and Analysis of Financial Condition and Results of Operations is attached to this
Form 6-K as Exhibit 99.2.
EXHIBIT
INDEX
| Exhibit |
|
Title |
| |
|
|
| 99.1 |
|
Unaudited Consolidated Financial Statements as of June 30, 2025, and for the six months ended June 30, 2025. |
| 99.2
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
| 101 |
|
The
following materials from Genenta’s Report on Form 6-K for the six months ended June 30, 2025, formatted in Inline XBRL (eXtensible
Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations and Comprehensive
Loss, (iii) the Consolidated Statements of Changes in Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows,
and (v) Notes to the Consolidated Financial Statements. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
GENENTA
SCIENCE S.P.A. |
| |
|
|
| Date:
October 10, 2025 |
By:
|
/s/
Richard B. Slansky |
| |
|
Richard
B. Slansky, Chief Financial Officer |
